GUCA2B

Across TCGA pan-cancer cohorts, GUCA2B mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of GUCA2B’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where GUCA2B mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types GUCA2B is over-expressed in tumor, although a few such as HNSC and PDAC show the opposite, repressed pattern.

HNSC, PDAC, and LSCC are the cancer types where GUCA2B tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in GUCA2B mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Male	III,IV	−1.148	<.001	8	view →
PDAC	Female	II,III,IV	−1.261	<.001	7	view →
LSCC	All	All	−0.809	<.001	4	view →
COAD	Female	III,IV	−0.325	.009	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

GUCA2B–HNSC

Open the HNSC breakdown →